Here’s how analysts see Galapagos NV (NASDAQ:GLPG) after this past week.

January 20, 2018 - By Maria Brooks

 Here's how analysts see Galapagos NV (NASDAQ:GLPG) after this past week.

Galapagos NV (NASDAQ:GLPG) Ratings Coverage

Among 9 analysts covering Galapagos NV (NASDAQ:GLPG), 6 have Buy rating, 0 Sell and 3 Hold. Therefore 67% are positive. Galapagos NV had 27 analyst reports since August 11, 2015 according to SRatingsIntel. The firm earned “Buy” rating on Friday, August 11 by Nomura. On Tuesday, August 30 the stock rating was initiated by Janney Capital with “Buy”. The stock has “Overweight” rating by Morgan Stanley on Monday, May 2. The firm has “Buy” rating by Cowen & Co given on Friday, July 28. On Friday, October 27 the stock rating was maintained by Stifel Nicolaus with “Buy”. On Friday, July 28 the stock rating was maintained by Stifel Nicolaus with “Hold”. The firm has “Hold” rating by RBC Capital Markets given on Friday, October 27. The firm has “Buy” rating by Stifel Nicolaus given on Thursday, September 14. The stock has “Hold” rating by RBC Capital Markets on Thursday, September 14. The stock has “Buy” rating by Cowen & Co on Thursday, August 10. Below is a list of Galapagos NV (NASDAQ:GLPG) latest ratings and price target changes.

08/01/2018 Broker: BTIG Research Rating: Buy New Target: $118.0 Maintain
20/11/2017 Broker: BTIG Research Rating: Buy New Target: $118.0 Maintain
07/11/2017 Broker: BTIG Research Rating: Buy New Target: $118.0 Maintain
27/10/2017 Broker: Stifel Nicolaus Rating: Buy New Target: $120.0 Maintain
27/10/2017 Broker: RBC Capital Markets Rating: Hold New Target: $102.0 Maintain
06/10/2017 Broker: Morgan Stanley Rating: Overweight Old Target: $92 New Target: $123 Maintain
14/09/2017 Broker: RBC Capital Markets Rating: Hold New Target: $98.0 Initiate
14/09/2017 Broker: Stifel Nicolaus Rating: Buy New Target: $120.0 Maintain
10/08/2017 Broker: BTIG Research Rating: Buy New Target: $98.0000 Maintain
11/08/2017 Broker: Nomura Rating: Buy Old Target: $108 New Target: $124 Maintain

The stock increased 2.68% or $2.94 during the last trading session, reaching $112.44. About 98,101 shares traded or 7.28% up from the average. Galapagos NV (NASDAQ:GLPG) has risen 65.27% since January 20, 2017 and is uptrending. It has outperformed by 48.57% the S&P500.

Galapagos NV, a clinical-stage biotechnology company, develops and commercializes novel medicines in Belgium, Croatia, France, and the Netherlands. The company has market cap of $5.49 billion. The companyÂ’s clinical stage programs include filgotinib, which is in Phase III clinical trial for the treatment of rheumatoid arthritis, CrohnÂ’s disease, and ulcerative colitis; GLPG1690, which is in Phase IIa clinical trial for the treatment of idiopathic pulmonary fibrosis; GLPG1972, which is in Phase 1 clinical trial for the treatment of osteoarthritis; and MOR106 that is in atopic dermatitis patients in Phase Ib trial. It currently has negative earnings. The firm has collaboration agreement with Gilead Sciences, Inc. for the development of filgotinib for inflammatory indications; Servier to develop GLPG1972; and AbbVie for discovery, development, and commercialization of potentiator and corrector molecules for the treatment of cystic fibrosis, as well as with MorphoSys for MOR106.

More notable recent Galapagos NV (NASDAQ:GLPG) news were published by: Benzinga.com which released: “30 Stocks Moving In Friday’s Mid-Day Session” on December 15, 2017, also Barrons.com with their article: “Galapagos Is More Attractive–But Don’t Buy It Just Yet” published on July 07, 2017, Benzinga.com published: “33 Biggest Movers From Friday” on December 18, 2017. More interesting news about Galapagos NV (NASDAQ:GLPG) were released by: Quotes.Wsj.com and their article: “Galapagos NV ADR” published on May 09, 2015 as well as Benzinga.com‘s news article titled: “Morgan Stanley Expects Galapagos Shares To Rise 10%” with publication date: August 10, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.